Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mylan N.V.    MYL   NL0011031208


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

MYL Bronstein, Gewirtz & Grossman, LLC Notifies Mylan N.V. Investors With Losses Exceeding $11,000,000 of Class Action and Lead Plaintiff Deadline: August 25, 2020

share with twitter share with LinkedIn share with facebook
07/03/2020 | 11:01am EDT

NEW YORK, July 3, 2020 /PRNewswire/ --Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mylan N.V. ("Mylan" or the "Company") (NASDAQ: MYL) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Mylan securities between February 16, 2016 and May 7, 2019, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/myl.        

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. 

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose rampant abuses of federal quality control regulations, including at Mylan's Morgantown facility. The complaint continues to allege that through a scheme implemented by Mylan's President, Mylan chemists manipulated quality control test data in order to create the facade that Mylan's drugs had achieved passing quality control results. Then, in November 2016, a whistleblower reported Mylan's conduct to the U.S. Food & Drug Administration. Consequently, Mylan was forced to reveal that it would be "restructuring" its Morgantown facility, including by terminating hundreds of employees, and reported a surprise quarterly loss on May 7, 2019. The complaint alleges that when the true details entered the market, investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/myl  or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Mylan you have until August 25, 2020 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com


View original content to download multimedia:http://www.prnewswire.com/news-releases/myl-shareholder-alert-bronstein-gewirtz--grossman-llc-notifies-mylan-nv-investors-with-losses-exceeding-11-000-000-of-class-action-and-lead-plaintiff-deadline-august-25--2020--301087781.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

© PRNewswire 2020
share with twitter share with LinkedIn share with facebook
Toute l'actualité sur MYLAN N.V.
08/13Zydus Cadila launches India's cheapest remdesivir version at $37 per vial
08/12MYLAN N : ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Mylan N.V. Investors of Imp..
08/12MYLAN N : and Sesame Workshop Partner to Provide Socio-Emotional Support Resourc..
08/11India's shortage of remdesivir is easing, says producer Cipla
08/09MYLAN N : ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Mylan N.V. Investors o..
08/06MYLAN N : Q2 2020 Non-GAAP Reconciliations
08/06Mylan tightens revenue estimates on COVID-19 pressure; shares fall
08/06MYLAN N : Reports Strong Second Quarter and First Half 2020 Results and Updates ..
08/06Mylan narrows annual revenue estimates on COVID-19 pressure
07/29Pfizer Sees Long-Term Vaccine Need -- WSJ
More news